Papers
17
Total Citations
278
H-Index
8
About
Felix Berlth is a leading surgeon-scientist whose work is reshaping the surgical management of esophageal and gastric cancers, with a particular focus on the evolution and validation of robotic-assisted minimally invasive techniques. His major contributions are anchored in high-impact clinical trials and large-scale registry studies. He is the lead author of the landmark ROBOT-2 trial, a randomized controlled trial comparing robot-assisted thoraco-laparoscopic esophagectomy (RAMIE) to conventional minimally invasive esophagectomy (MIE) for resectable esophageal adenocarcinoma, a study that has garnered over 100 citations and is pivotal in defining the role of robotics in oncologic esophagectomy. Beyond this, Berlith has been instrumental in establishing the Upper GI International Robotic Association (UGIRA) Esophageal Registry, providing the first comprehensive, real-world snapshot of RAMIE outcomes worldwide, with his 2024 analysis already cited 24 times. He has also systematically detailed and standardized the technical nuances of RAMIE, from the abdominal phase to circular stapled anastomoses, and has advanced the field of robotic gastrectomy. His work, consistently cited in the top surgical journals, provides the evidence base that is guiding the global adoption of robotic platforms for upper GI malignancies, making him a central figure in the transition toward precision, minimally invasive oncologic surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2Minimally invasive esophagectomy: clinical evidence and surgical techniques34 citations · 2020
- 3
- 4
- 5
- 6
- 7Minimal-invasive gastrectomy: what the west can learn from the east?12 citations · 2018
- 8
- 9
- 10